Formonetin

Formonetin

SCHEMBL4728656

COc1ccc(-c2coc3cc(O)c(O)cc3c2=O)cc1

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.83
KLK7 P49862 1/20 0.83
MEN1 O00255 6/20 0.74
KMT2A Q03164 6/20 0.74
MAPT P10636 6/20 0.74
ALDH1A1 P00352 6/20 0.74
SMN1; SMN2 Q16637 5/20 0.74
CYP3A4 P08684 5/20 0.74
TP53 P04637 4/20 0.74
KDM4E B2RXH2 4/20 0.74
MAOA P21397 4/20 0.74
MAOB P27338 4/20 0.74
CYP2D6 P10635 3/20 0.74
CYP2C9 P11712 3/20 0.74
CYP2C19 P33261 3/20 0.74
HPGD P15428 3/20 0.74
HSD17B10 Q99714 3/20 0.74
HDAC6 Q9UBN7 2/20 0.74
CYP1B1 Q16678 2/20 0.74
BCL2 P10415 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29448332 0.91 RAB9A (0.90) RAB9AKLK7MEN1KMT2AMAPT
Castanin SCHEMBL572274 0.91 RAB9A (1.00) RAB9AKLK7MEN1KMT2AMAPT
SCHEMBL13169484 0.89 RAB9A (0.74) RAB9AKLK7MEN1KMT2AMAPT
Formononetin SCHEMBL62915 0.85 KDM4E (1.00) RAB9AKLK7MEN1KMT2AMAPT
Formononetin SCHEMBL15271536 0.85 KDM4E (1.00) RAB9AKLK7MEN1KMT2AMAPT
Formononetin SCHEMBL29361145 0.85 KDM4E (1.00) RAB9AKLK7MEN1KMT2AMAPT
SCHEMBL30573375 0.84 RAB9A (0.81) RAB9AKLK7MEN1KMT2AMAPT
SCHEMBL7030328 0.84 RAB9A (0.81) RAB9AKLK7MEN1KMT2AMAPT
SCHEMBL28495484 0.84 RAB9A (0.65) RAB9AKLK7MEN1KMT2AMAPT
SCHEMBL571576 0.84 XDH (0.84) RAB9AKLK7MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293565-A1 USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2023-09-21 US claimed
CN-113130001-B Screening method for compatibility of natural compound and anti-tumor compound 甘肃中医药大学 2023-07-18 CN claimed
CN-116249520-A Blocking replication of SARS-COV-2 and other pathogenic viruses using WNT/beta-catenin pathway inhibitors 阿尔伯塔大学理事会 2023-06-09 CN claimed
EP-4188378-A1 USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES The Governors of the University of Alberta (CA) 2023-06-07 EP claimed
CN-114115182-A Motor controller test system and method 中国商用飞机有限责任公司北京民用飞机技术研究中心 2022-03-01 CN claimed
WO-2022020967-A1 USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2022-02-03 WO claimed
US-20260034152-A1 Influx Vitamins and Drinks, with Zinc Ionophoric Influx BLACK STEPHEN (US) 2026-02-05 US disclosed
US-20250367337-A1 OZONE SPRAY METHODS SEEGROW SOLUTIONS LTD (GB) 2025-12-04 US disclosed
WO-2025087805-A1 PRESSURE MEASURING DEVICE Ph-Instruments GmbH (AT) 2025-05-01 WO disclosed
CN-116283873-B Preparation method of kyunonin and application of kyunonin in resisting ischemic cerebral apoplexy and Alzheimer's disease 扬州大学 2025-02-21 CN disclosed
US-20250008868-A1 VALVED DOSING SYSTEM SEEGROW HOLDINGS LIMITED (GB) 2025-01-09 US disclosed
WO-2024225151-A1 LEGUME-DERIVED COMPOSITION AND METHOD FOR PRODUCING SAME, AND CHICKEN GIZZARD-DERIVED COMPOSITION AND METHOD FOR PRODUCING SAME サントリーホールディングス株式会社 2024-10-31 WO disclosed
US-12116964-B2 Dewatering fuel in a diesel locomotive Siemens Mobility GmbH (DE) 2024-10-15 US disclosed
US-4390559-A AND EDIBLE FAT OR OIL Z-L LIMITED PARTNERSHIP (US) 1983-06-28 US disclosed
US-4366082-A Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same Z-L LIMITED PARTNERSHIP (US) 1982-12-28 US disclosed
US-4366248-A USING SOYBEANS WITH THE FUNGUS RHIZOPUS Z-L LIMITED PARTNERSHIP (US) 1982-12-28 US disclosed
EP-0027796-A4 CHROMAN AND CHROMANON-4 DERIVATIVES, PROCESS FOR THEIR PREPARATION, ANTIOXIDANT COMPOSITIONS CONTAINING SAME AND THEIR USE FOR STABILIZING EDIBLE FATS AND OILS. Z L LTD PARTNERSHIP (US) 1981-08-31 EP disclosed
EP-0027796-A1 CHROMAN AND CHROMANON-4 DERIVATIVES, PROCESS FOR THEIR PREPARATION, ANTIOXIDANT COMPOSITIONS CONTAINING SAME AND THEIR USE FOR STABILIZING EDIBLE FATS AND OILS. Z L LTD PARTNERSHIP (US) 1981-05-06 EP disclosed
US-4264509-A STORAGE STABILITY FOR FOODS CONTAINING OILS AND FATS Z-L LIMITED PARTNERSHIP (US) 1981-04-28 US disclosed
WO-1980002098-A1 ISOFLAVONES AND RELATED COMPOUNDS,METHODS OF PREPARING AND USING AND ANTIOXIDANT COMPOSITIONS CONTAINING SAME PARTNERSHIP LTD (US) 1980-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034152-A1 Influx Vitamins and Drinks, with Zinc Ionophoric Influx KCNN3, VDR, KCNN2 RAB9A 2350/4885KLK7 1122/4885MEN1 2709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.